Alfredo Falcone

List of Publications by Year
in descending order

395 papers	27,623 citations	10979 71 h-index	6831 155 g-index
409 all docs	409 docs citations	409 times ranked	25612 citing authors

#	Article	IF	Citations
1	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. Cancer Immunology, Immunotherapy, 2022, 71, 865-874.	2.0	11
2	Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. Journal of the National Cancer Institute, 2022, 114, 271-279.	3.0	27
3	Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives. Cancer Treatment Reviews, 2022, 102, 102301.	3.4	17
4	A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients. Npj Breast Cancer, 2022, 8, 33.	2.3	3
5	In Pancreatic Adenocarcinoma Alpha-Synuclein Increases and Marks Peri-Neural Infiltration. International Journal of Molecular Sciences, 2022, 23, 3775.	1.8	5
6	Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials. European Journal of Cancer, 2022, 172, 22-30.	1.3	3
7	Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. British Journal of Cancer, 2021, 124, 183-190.	2.9	7
8	Pharmacodynamic biomarkers in metronomic chemotherapy: multiplex cytokine measurements in gastrointestinal cancer patients. Clinical and Experimental Medicine, 2021, 21, 149-159.	1.9	5
9	Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm. Cancer Treatment Reviews, 2021, 92, 102135.	3.4	2
10	Clinical Validation of a Machine-learningâ€“derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. Clinical Cancer Research, 2021, 27, 1174-1183.	3.2	28
11	FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis. Oncologist, 2021, 26, 302-309.	1.9	9
12	Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer. Pharmacogenomics Journal, 2021, 21, 285-295.	0.9	3
13	Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN). Cancers, 2021, 13, 1304.	1.7	2
14	RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC. Molecular Cancer Therapeutics, 2021, 20, 1153-1160.	1.9	1
15	BRAFV600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. Journal of the National Cancer Institute, 2021, 113, 1386-1395.	3.0	17
16	Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade. Journal of the Endocrine Society, 2021, 5, bvab093.	0.1	3
17	Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients. Scientific Reports, 2021, 11, 12191.	1.6	3
18	Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer. European Journal of Cancer, 2021, 150, 133-142.	1.3	1

#	Article	IF	Citations
19	Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. Journal of the National Cancer Institute, 2021, 113, 1705-1713.	3.0	12
20	Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer. Future Oncology, 2021, 17, 2315-2324.	1.1	6
21	Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients. Clinical Colorectal Cancer, 2021, 20, 314-317.	1.0	12
22	CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. British Journal of Cancer, 2021, 125, 839-845.	2.9	9
23	Zebrafish Patient-Derived Xenografts Identify Chemo-Response in Pancreatic Ductal Adenocarcinoma Patients. Cancers, 2021, 13, 4131.	1.7	8
24	Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer. JAMA Oncology, 2021, 7, 1529.	3.4	80
25	Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. European Journal of Cancer, 2021, 153, 16-26.	1.3	5
26	Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. European Journal of Cancer, 2021, 155, 73-84.	1.3	13
27	Detailing the ultrastructureâ€™s increase of prion protein in pancreatic adenocarcinoma. World Journal of Gastroenterology, 2021, 27, 7324-7339.	1.4	2
28	Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells. Investigational New Drugs, 2020, 38, 92-98.	1.2	3
29	Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients. Clinical Breast Cancer, 2020, 20, e89-e98.	1.1	8
30	Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients. Journal of Cancer Research and Clinical Oncology, 2020, 146, 493-501.	1.2	7
31	Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients. Cancers, 2020, 12, 2947.	1.7	4
32	Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapyâ€”a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. European Journal of Cancer, 2020, 139, 81-89.	1.3	17
33	AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. European Journal of Cancer, 2020, 138, 1-10.	1.3	23
34	Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer. , 2020, 8, e001714.		23
35	AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. BMC Cancer, 2020, 20, 683.	1.1	53
36	First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age?. European Journal of Cancer, 2020, 137, 108-116.	1.3	11

#	Article	IF	Citations
37	Perioperative Morbidity Following Cytoreductive Surgery Combined with Intraperitoneal Chemohyperthermia in a Novel Italian Centre. European Journal of Surgical Oncology, 2020, 46, e160-e161.	0.5	0
38	Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib. Molecular Cancer Therapeutics, 2020, 19, 2146-2154.	1.9	18
39	Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2020, 38, 3314-3324.	0.8	139
40	Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge. Cancers, 2020, 12, 2317.	1.7	37
41	Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. European Journal of Cancer, 2020, 135, 78-88.	1.3	10
42	Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study. ESMO Open, 2020, 5, e000698.	2.0	26
43	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncology, The, 2020, 21, 497-507.	5.1	196
44	Immune Checkpoint Inhibitors in Esophageal Cancers: Are We Finally Finding the Right Path in the Mist?. International Journal of Molecular Sciences, 2020, 21, 1658.	1.8	22
45	A Model of a Zebrafish Avatar for Co-Clinical Trials. Cancers, 2020, 12, 677.	1.7	36
46	Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System Activation. Journal of Molecular Diagnostics, 2020, 22, 685-698.	1.2	11
47	TRIBE2 results and toxicity â€“ Authors' reply. Lancet Oncology, The, 2020, 21, e300-e301.	5.1	0
48	Management of Peritoneal Carcinomatosis With Cytoreductive Surgery Combined With Intraperitoneal Chemohyperthermia at a Novel Italian Center. In Vivo, 2020, 34, 2061-2066.	0.6	3
49	Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial. Cancers, 2020, 12, 1742.	1.7	4
50	Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab. Expert Opinion on Biological Therapy, 2020, 20, 319-326.	1.4	12
51	Application of the ESR iGuide clinical decision support system to the imaging pathway of patients with hepatocellular carcinoma and cholangiocarcinoma: preliminary findings. Radiologia Medica, 2020, 125, 531-537.	4.7	31
52	Tumor Regression Grading Assessment in Locally Advanced Pancreatic Cancer After Neoadjuvant FOLFIRINOX: Interobserver Agreement and Prognostic Implications. Frontiers in Oncology, 2020, 10, 64.	1.3	14
53	First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design. Future Oncology, 2020, 16, 21-29.	1.1	20
54	Duration of oxaliplatinâ€based adjuvant chemotherapy in patients with Stage III or highâ€risk Stage II resected colon cancer. International Journal of Cancer, 2020, 146, 2652-2654.	2.3	3

#	Article	IF	Citations
55	Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study. Advances in Therapy, 2020, 37, 1145-1155.	1.3	102
56	Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study. Targeted Oncology, 2020, 15, 115-126.	1.7	15
57	A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. European Journal of Cancer, 2020, 131, 89-97.	1.3	9
58	HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer. Oncologist, 2020, 25, 886-893.	1.9	27
59	The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled Analysis. Cancers, 2020, 12, 1022.	1.7	16
60	Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. Clinical Colorectal Cancer, 2020, 19, 191-199.e6.	1.0	20
61	FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable metastatic colorectal cancer (mCRC): A meta-analysis of individual patient data (IPD) from five randomized trials.. Journal of Clinical Oncology, 2020, 38, 4015-4015.	0.8	12
62	PNNandKCNQ1OT1Can Predict the Efficacy of Adjuvant Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer Patients. Oncology Research, 2020, 28, 631-644.	0.6	10
63	Use of zebrafish embryos as avatar of patients with pancreatic cancer: A new xenotransplantation model towards personalized medicine. World Journal of Gastroenterology, 2020, 26, 2792-2809.	1.4	23
64	Clinical and economic effect of administration of red blood product transfusions in an outpatient supportive care cancer service. Biomedical Reports, 2020, 12, 199-203.	0.9	0
65	Circulating Tumor DNA Analysis in Colorectal Cancer: From Dream to Reality. JCO Precision Oncology, 2019, 3, 1-14.	1.5	11
66	Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study. Cancers, 2019, 11, 939.	1.7	12
67	Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients. Breast Cancer Research and Treatment, 2019, 178, 57-62.	1.1	71
68	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer. JAMA Oncology, 2019, 5, 1268.	3.4	70
69	Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study. European Journal of Cancer, 2019, 123, 146-154.	1.3	46
70	Evaluation of Continuous Tumor-Sizeâ€"Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. JAMA Network Open, 2019, 2, e1911750.	2.8	6
71	Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses. Clinical Colorectal Cancer, 2019, 18, 269-279.e5.	1.0	4
72	Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. Clinical Colorectal Cancer, 2019, 18, e394-e401.	1.0	13

#	Article	IF	Citations
73	Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib. Pharmacogenomics Journal, 2019, 19, 455-464.	0.9	5
74	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 420-435.	5.1	191
75	Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?. Pharmacogenomics Journal, 2019, 19, 465-472.	0.9	16
76	Quantitative evidence for early metastatic seeding in colorectal cancer. Nature Genetics, 2019, 51, 1113-1122.	9.4	315
77	Androgen receptor (AR) splice variant 7 and fullâ€length AR expression is associated with clinical outcome: a translational study in patients with castrateâ€resistant prostate cancer. BJU International, 2019, 124, 693-700.	1.3	32
78	Interprofessional spiritual care in oncology: a literature review. ESMO Open, 2019, 4, e000465.	2.0	61
79	Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncology, The, 2019, 20, 849-861.	5.1	368
80	Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component. Clinical Colorectal Cancer, 2019, 18, 116-124.	1.0	7
81	Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. European Journal of Cancer, 2019, 111, 138-147.	1.3	4
82	AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A metaâ€analysis using TRIBE, MAVERICC and FIRE3. International Journal of Cancer, 2019, 145, 2082-2090.	2.3	4
83	Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. ESMO Open, 2019, 4, e000489.	2.0	14
84	Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics. Biochemical Pharmacology, 2019, 164, 94-105.	2.0	14
85	DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. Pharmacogenomics Journal, 2019, 19, 556-563.	0.9	35
86	Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. European Journal of Cancer, 2019, 109, 175-182.	1.3	25
87	Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial. European Journal of Cancer, 2019, 110, 32-41.	1.3	25
88	Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer. British Journal of Cancer, 2019, 120, 522-526.	2.9	11
89	Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable. ESMO Open, 2019, 4, e000496.	2.0	3
90	BRAF mutant metastatic colorectal cancers: new arrows in our quiver. Annals of Translational Medicine, 2019, 7, S367-S367.	0.7	1

#	Article	IF	Citations
91	Atypical RAS Mutations in Metastatic Colorectal Cancer. JCO Precision Oncology, 2019, 3, 1-11.	1.5	1
92	Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. Oncologist, 2019, 24, 185-192.	1.9	89
93	Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. Clinical Colorectal Cancer, 2019, 18, e8-e19.	1.0	12
94	Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan. JAMA Oncology, 2019, 5, 343.	3.4	280
95	The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer. Pharmacogenomics, 2019, 20, 49-68.	0.6	23
96	Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial. Oncotarget, 2019, 10, 2791-2792.	0.8	0
97	FLOaTing toward new standards in locally advanced resectable gastroesophageal cancer. Journal of Thoracic Disease, 2019, 11, 5694-5700.	0.6	1
98	PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC. British Journal of Cancer, 2018, 118, 820-824.	2.9	190
99	Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. Investigational New Drugs, 2018, 36, 709-714.	1.2	8
100	An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study. Expert Review of Pharmacoeconomics and Outcomes Research, 2018, 18, 435-446.	0.7	9
101	Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. Clinical Colorectal Cancer, 2018, 17, e471-e488.	1.0	12
102	Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. Journal of the National Cancer Institute, 2018, 110, 638-648.	3.0	90
103	Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer. JAMA Oncology, 2018, 4, 529.	3.4	87
104	EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas. Cancer Biomarkers, 2018, 21, 731-741.	0.8	16
105	Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Handâ€“Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. Clinical Colorectal Cancer, 2018, 17, e395-e414.	1.0	25
106	Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. British Journal of Cancer, 2018, 118, 955-965.	2.9	17
107	Integrated safety summary for trifluridine/tipiracil (TAS-102). Anti-Cancer Drugs, 2018, 29, 89-96.	0.7	12
108	A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. Clinical Cancer Research, 2018, 24, 784-793.	3.2	23

#	Article	IF	Citations
109	Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680â€“7. European Urology, 2018, 73, e11-e12.	0.9	0
110	Optimization of biomarkers-based classification scores as progression-free survival predictors: an intuitive graphical representation. Future Science OA, 2018, 4, FSO346.	0.9	1
111	Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTALÂand COIN-B trials in the ARCAD database. European Journal of Cancer, 2018, 103, 205-213.	1.3	13
112	BRAF V600E Mutation as a Negative Prognostic Determinant in Resected Colorectal Liver Metastases. JAMA Surgery, 2018, 153, 1162.	2.2	0
113	Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. Oncologist, 2018, 23, 1178-1187.	1.9	46
114	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. European Journal of Cancer, 2018, 100, 35-45.	1.3	29
115	Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. Pharmacogenomics Journal, 2018, 18, 623-632.	0.9	8
116	TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. ESMO Open, 2018, 3, e000403.	2.0	20
117	A retrospective study of trifluridine/tipiracil in pretreated metastatic colorectal cancer patients in clinical practice. Colorectal Cancer, 2018, 7, CRC01.	0.8	3
118	The Winding Roadmap of Biomarkers toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer. International Journal of Molecular Sciences, 2018, 19, 2298.	1.8	4
119	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet, The, 2018, 392, 123-133.	6.3	984
120	NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. PLoS ONE, 2018, 13, e0193640.	1.1	5
121	Locally advanced gastro-oesophageal cancer: Recent therapeutic advances and research directions. Cancer Treatment Reviews, 2018, 69, 90-100.	3.4	21
122	Liquid biopsy to predict benefit from rechallenge with cetuximab (cet) + irinotecan (iri) in RAS/BRAF wild-type metastatic colorectal cancer patients (pts) with acquired resistance to first-line cet+iri: Final results and translational analyses of the CRICKET study by GONO.. Journal of Clinical Oncology, 2018, 36, 12007-12007.	0.8	13
123	DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. Oncotarget, 2018, 9, 7859-7866.	0.8	25
124	Current status and perspectives in immunotherapy for metastatic melanoma. Oncotarget, 2018, 9, 12452-12470.	0.8	73
125	Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer. Pharmacogenomics Journal, 2017, 17, 258-264.	0.9	79
126	Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. British Journal of Cancer, 2017, 116, 318-323.	2.9	29

#	Article	IF	Citations
127	First-line therapy for mCRC â€" the influence of primary tumour location on the therapeutic algorithm. Nature Reviews Clinical Oncology, 2017, 14, 113-113.	12.5	35
128	Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients. Breast, 2017, 31, 186-191.	0.9	11
129	The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab. British Journal of Cancer, 2017, 117, 315-321.	2.9	19
130	Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. European Journal of Cancer, 2017, 82, 237-246.	1.3	38
131	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	183
132	Single nucleotide polymorphisms in the IGFâ€IRS pathway are associated with outcome in mCRC patients enrolled in the FIREâ€3 trial. International Journal of Cancer, 2017, 141, 383-392.	2.3	10
133	Multimodality treatment of locally advanced squamous cell carcinoma of the oesophagus: A comprehensive review and network meta-analysis. Critical Reviews in Oncology/Hematology, 2017, 114, 24-32.	2.0	22
134	Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36Âmonths. Experimental Hematology and Oncology, 2017, 6, 6.	2.0	38
135	Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. European Journal of Cancer, 2017, 77, 13-20.	1.3	19
136	Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. European Journal of Cancer, 2017, 73, 74-84.	1.3	54
137	Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING caseâ€"control study. Annals of Oncology, 2017, 28, 3009-3014.	0.6	72
138	Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer. Scientific Reports, 2017, 7, 7931.	1.6	66
139	Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatinâ€based chemotherapy in patients with metastatic colorectal cancer. Cancer, 2017, 123, 4506-4514.	2.0	8
140	Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. Annals of Oncology, 2017, 28, 2780-2785.	0.6	28
141	Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial. ESMO Open, 2017, 2, e000261.	2.0	22
142	Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. ESMO Open, 2017, 2, e000241.	2.0	10
143	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1688-1700.	5.1	451
144	RET rearrangements define a new and rare molecular subtype of metastatic colorectal cancer (mCRC). Annals of Oncology, 2017, 28, iii140-iii141.	0.6	0

#	Article	IF	Citations
145	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. European Journal of Cancer, 2017, 82, 16-24.	1.3	40
146	Prognostic and predictive role of neutrophils/lymphocytes ratio in metastatic colorectal cancer: A retrospective analysis of the TRIBE study by Gono. Annals of Oncology, 2017, 28, iii141-iii142.	0.6	0
147	TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. BMC Cancer, 2017, 17, 408.	1.1	28
148	Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. Annals of Oncology, 2017, 28, 555-561.	0.6	43
149	Impact of a supportive care service for cancer outpatients: management and reduction of hospitalizations. Preliminary results of an integrated model of care. Supportive Care in Cancer, 2017, 25, 209-212.	1.0	18
150	The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. European Urology, 2017, 71, 680-687.	0.9	213
151	Real-world dosing of regorafenib in metastatic colorectal cancer (mCRC): Interim analysis from the prospective, observational CORRELATE study. Annals of Oncology, 2017, 28, iii10.	0.6	6
152	Adjuvant Chemoradiotherapy (Gemcitabine-based) in Pancreatic Adenocarcinoma: The Pisa University Experience. Tumori, 2017, 103, 577-582.	0.6	3
153	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en CancÃ©rologie Digestive Database. Journal of Clinical Oncology, 2017, 35, 1929-1937.	0.8	37
154	Regorafenib: lights and shadows of antiangiogenic therapies in gastric cancer. Translational Gastroenterology and Hepatology, 2017, 2, 11-11.	1.5	0
155	Novel prognostic markers for epithelioid malignant pleural mesothelioma.. Journal of Clinical Oncology, 2017, 35, e20028-e20028.	0.8	3
156	Prognostic relevance of a T-type calcium channels gene signature in solid tumours: A correlation ready for clinical validation. PLoS ONE, 2017, 12, e0182818.	1.1	17
157	Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment. Oncotarget, 2017, 8, 86056-86065.	0.8	13
158	Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA. Oncotarget, 2017, 8, 13611-13619.	0.8	81
159	Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer. Anticancer Research, 2017, 37, 315-320.	0.5	21
160	Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis. Cancer Research and Treatment, 2017, 49, 834-845.	1.3	12
161	Variations of circulating KRAS amount as a biomarker to monitor chemotherapy response in pancreatic cancer.. Journal of Clinical Oncology, 2017, 35, e15794-e15794.	0.8	1
162	Firstâ€line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors. International Journal of Cancer, 2016, 139, 938-945.	2.3	38

#	Article	IF	Citations
163	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology, 2016, 27, 1386-1422.	0.6	2,545
164	Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients. Oncology, 2016, 91, 283-288.	0.9	5
165	Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT) Tj ETQq1 1 0.784314 rgBT /Ove	2.8	28
166	A still missing piece of the FIRE-3 puzzle. Lancet Oncology, The, 2016, 17, e515.	5.1	0
167	Comment on: â€˜Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohortâ€™. British Journal of Cancer, 2016, 114, e8-e8.	2.9	1
168	Apatinib in Advanced Gastric Cancer: A Doubtful Step Forward. Journal of Clinical Oncology, 2016, 34, 3822-3823.	0.8	27
169	Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients. Investigational New Drugs, 2016, 34, 760-770.	1.2	29
170	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. Oncologist, 2016, 21, 988-994.	1.9	94
171	Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients. Oncology, 2016, 91, 311-316.	0.9	11
172	Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncology, The, 2016, 17, 1709-1719.	5.1	442
173	Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients. Scientific Reports, 2016, 6, 25195.	1.6	25
174	Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab. Molecular Cancer Therapeutics, 2016, 15, 1740-1745.	1.9	9
175	Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature. Future Oncology, 2016, 12, 901-908.	1.1	14
176	FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. Annals of Oncology, 2016, 27, 843-849.	0.6	46
177	Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. British Journal of Cancer, 2016, 114, 30-36.	2.9	56
178	Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. Journal of Clinical Oncology, 2016, 34, 144-150.	0.8	116
179	FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. World Journal of Gastroenterology, 2016, 22, 6987.	1.4	68
180	TRIBE study: are all three cytotoxic drugs crucial? â€“ Authors' reply. Lancet Oncology, The, 2015, 16, e578-e579.	5.1	0

#	Article	IF	Citations
181	Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data. Journal of Experimental and Clinical Cancer Research, 2015, 34, 156.	3.5	54
182	Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer. BMC Cancer, 2015, 15, 874.	1.1	10
183	Small-Bowel Neuroendocrine Tumor and Retroperitoneal Fibrosis: Efficacy of Octreotide and Tamoxifen. Tumori, 2015, 101, e24-e28.	0.6	5
184	FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer. New England Journal of Medicine, 2015, 372, 290-292.	13.9	11
185	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nature Medicine, 2015, 21, 795-801.	15.2	809
186	A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs. Journal of Gastrointestinal Cancer, 2015, 46, 201-211.	0.6	199
187	First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2015, 96, 156-166.	2.0	61
188	Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2015, 107, .	3.0	385
189	First-line chemotherapy for mCRCâ€"a review and evidence-based algorithm. Nature Reviews Clinical Oncology, 2015, 12, 607-619.	12.5	138
190	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncology, The, 2015, 16, 937-948.	5.1	286
191	BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Annals of Oncology, 2015, 26, 2092-2097.	0.6	137
192	Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer. New England Journal of Medicine, 2015, 372, 1909-1919.	13.9	1,027
193	BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. British Journal of Cancer, 2015, 112, 1921-1928.	2.9	146
194	Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Annals of Oncology, 2015, 26, 1188-1194.	0.6	153
195	Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials. Annals of Oncology, 2015, 26, 2450-2456.	0.6	29
196	Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. Molecular Cancer Therapeutics, 2015, 14, 2374-2381.	1.9	4
197	TAS-102 for the treatment of metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2015, 15, 1283-1292.	1.1	12
198	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncology, The, 2015, 16, 1306-1315.	5.1	835

#	Article	IF	Citations
199	Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. Annals of Oncology, 2015, 26, 2503.	0.6	18
200	MRI tumor volume reduction rate vs tumor regression grade in the pre-operative re-staging of locally advanced rectal cancer after chemo-radiotherapy. European Journal of Radiology, 2015, 84, 2438-2443.	1.2	32
201	Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer. Future Oncology, 2015, 11, 323-331.	1.1	9
202	Role ofNRASmutations as prognostic and predictive markers in metastatic colorectal cancer. International Journal of Cancer, 2015, 136, 83-90.	2.3	126
203	Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database. Journal of Clinical Oncology, 2015, 33, 22-28.	0.8	87
204	Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. Pharmacogenomics Journal, 2015, 15, 69-76.	0.9	25
205	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): Updated survival results and final molecular subgroups analyses.. Journal of Clinical Oncology, 2015, 33, 3510-3510.	0.8	8
206	FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group.. Journal of Clinical Oncology, 2015, 33, 657-657.	0.8	17
207	Genetic interaction ofP2X7receptor andVEGFR-2polymorphisms identifies a favorable prognostic profile in prostate cancer patients. Oncotarget, 2015, 6, 28743-28754.	0.8	21
208	Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management. Oncotarget, 2015, 6, 33982-33992.	0.8	46
209	Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Oncotarget, 2015, 6, 31604-31612.	0.8	30
210	KRAS Early Testing: Consensus Initiative and Cost-Effectiveness Evaluation for Metastatic Colorectal Patients in an Italian Setting. PLoS ONE, 2014, 9, e85897.	1.1	12
211	Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. Pharmacogenomics, 2014, 15, 1985-1999.	0.6	16
212	Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy. Future Oncology, 2014, 10, 285-304.	1.1	13
213	Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. Pharmacogenomics, 2014, 15, 1701-1715.	0.6	4
214	KRAS and BRAF genotyping of synchronous colorectal carcinomas. Oncology Letters, 2014, 7, 1532-1536.	0.8	7
215	Not only chemotherapy in the second-line treatment of metastatic gastric cancer. Annals of Oncology, 2014, 25, 544-545.	0.6	4
216	Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castrationâ€resistant prostate cancer patients. Cancer, 2014, 120, 3923-3931.	2.0	33

#	Article	IF	Citations
217	Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. Annals of Oncology, 2014, 25, 1373-1378.	0.6	84
218	Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients. Pharmacogenomics Journal, 2014, 14, 322-327.	0.9	11
219	Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: A systematic review. World Journal of Gastroenterology, 2014, 20, 6081.	1.4	24
220	Biomarkers and Response to Bevacizumabâ€"Letter. Clinical Cancer Research, 2014, 20, 1056-1057.	3.2	8
221	EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. Targeted Oncology, 2014, 9, 205-214.	1.7	27
222	Dedicated supportive care team at the oncology unit: a model of simultaneous care for cancer patients. Supportive Care in Cancer, 2014, 22, 867-868.	1.0	7
223	Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. British Journal of Cancer, 2014, 110, 2165-2169.	2.9	69
224	Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer. New England Journal of Medicine, 2014, 371, 1609-1618.	13.9	845
225	Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. Expert Review of Molecular Diagnostics, 2014, 14, 453-468.	1.5	17
226	Modified FOLFOXIRI plus cetuximab (cet) as induction treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Preliminary results of the phase II randomized Macbeth trial by GONO group.. Journal of Clinical Oncology, 2014, 32, 3596-3596.	0.8	4
227	The Role of Metronomic Chemotherapy in the Treatment of Metastatic Colorectal Cancer Patients. , 2014, , 135-142.		0
228	Electrochemotherapy and its controversial results in patients with head and neck cancer. Anticancer Research, 2014, 34, 967-72.	0.5	11
229	Adjuvant Systemic Chemotherapy After Putative Curative Resection of Colorectal Liver and Lung Metastases. Clinical Colorectal Cancer, 2013, 12, 188-194.	1.0	28
230	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, The, 2013, 381, 303-312.	6.3	2,276
231	Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. British Journal of Cancer, 2013, 108, 2549-2556.	2.9	51
232	Could Interferon Still Play a Role in Metastatic Renal Cell Carcinoma? A Randomized Study of Two Schedules of Sorafenib Plus Interferon-Alpha 2a (RAPSODY). European Urology, 2013, 63, 254-261.	0.9	29
233	The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms. Annals of Oncology, 2013, 24, 734-741.	0.6	83
234	Supportive care and not only palliative care in the route of cancer patients. Supportive Care in Cancer, 2013, 21, 657-658.	1.0	7

#	Article	IF	Citations
235	Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients. European Journal of Cancer, 2013, 49, 1501-1508.	1.3	19
236	Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment. Cancer Biology and Therapy, 2013, 14, 467-468.	1.5	5
237	FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS,) Tj ETQq1 1 0.784314 rgBT /Overlock Nord Ovest (GONO). Annals of Oncology, 2013, 24, 2062-2067.	0.6	86
238	Reply: Comment on â€˜Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumabâ€™. British Journal of Cancer, 2013, 109, 3129-3130.	2.9	3
239	VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. British Journal of Cancer, 2013, 109, 957-964.	2.9	41
240	FOLFOXIRI/Bevacizumab Versus FOLFIRI/Bevacizumab as First-Line Treatment in Unresectable Metastatic Colorectal Cancer: Results of Phase III Tribe Trial by Gono Group. Annals of Oncology, 2013, 24, iv21.	0.6	5
241	Long-Survivors with Lung Metastases and Kras Mutations Have an Increased Risk to Develop Brain Metastases From Colorectal Cancer. Annals of Oncology, 2013, 24, iv15.	0.6	1
242	Prospective Analysis of the Early Modulation of Plasma Amphiregulin During Treatment with Cetuximab and Irinotecan in Metastatic Colorectal Cancer Patients. Annals of Oncology, 2013, 24, iv28.	0.6	0
243	Conference Scene: Annual Meeting of the American Society of Clinical Oncology. Colorectal Cancer, 2013, 2, 401-404.	0.8	0
244	Oral multikinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer. Colorectal Cancer, 2013, 2, 411-417.	0.8	1
245	Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab. PLoS ONE, 2013, 8, e66774.	1.1	64
246	Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study. Anticancer Research, 2013, 33, 3487-94.	0.5	53
247	High Let-7a MicroRNA Levels in KRAS-Mutated Colorectal Carcinomas May Rescue Anti-EGFR Therapy Effects in Patients with Chemotherapy-Refractory Metastatic Disease. Oncologist, 2012, 17, 823-829.	1.9	74
248	Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Annals of Oncology, 2012, 23, 2072-2077.	0.6	108
249	Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer. Annals of Oncology, 2012, 23, 135-141.	0.6	79
250	Prognostic Value of CD133 Caused by Mutant K-Ras and B-Rafâ€"Letter. Clinical Cancer Research, 2012, 18, 4473-4473.	3.2	0
251	A Phase II Trial of Fixed-Dose Rate Gemcitabine plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients. Oncology, 2012, 82, 75-82.	0.9	7
252	Resectable liver metastases from colorectal cancer: where we are now and where do we go from here?. Colorectal Cancer, 2012, 1, 397-411.	0.8	0

#	Article	IF	Citations
253	Analysis of HER-3, insulin growth factor-1, nuclear factor-ĸB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecanâ€“cetuximab. Annals of Oncology, 2012, 23, 1706-1712.	0.6	34
254	EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. Cancer and Metastasis Reviews, 2012, 31, 753-761.	2.7	148
255	Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?. Annals of Oncology, 2012, 23, 2313-2318.	0.6	170
256	Outcome of Second-Line Treatment After First-Line Chemotherapy With the GONO FOLFOXIRI Regimen. Clinical Colorectal Cancer, 2012, 11, 71-76.	1.0	17
257	EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle. Annals of Oncology, 2012, 23, 1370-1371.	0.6	7
258	An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Annals of Oncology, 2012, 23, 1207-1213.	0.6	40
259	Upfront Chemotherapy Regimens in Unresectable Disease: One, Two, or Three Cytotoxics?. Current Colorectal Cancer Reports, 2012, 8, 153-160.	1.0	0
260	Pharmacogenetic Concerns in Metastatic Colorectal Cancer Therapy. Current Colorectal Cancer Reports, 2012, 8, 263-271.	1.0	1
261	High-Throughput MicroRNA (miRNAs) Arrays Unravel the Prognostic Role of MiR-211 in Pancreatic Cancer. PLoS ONE, 2012, 7, e49145.	1.1	67
262	O-0023 Phase 3 Correct Trial of Regorafenib in Metastatic Colorectal Cancer (mCRC). Annals of Oncology, 2012, 23, iv15-iv16.	0.6	1
263	PD-0009 Primary Tumor Location is a Major Independent Prognostic Factor for Mcrc Patients. Annals of Oncology, 2012, 23, iv22.	0.6	0
264	P-0262 Prospective Evaluation of Candidate Snps of Vegf/Vegfr Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line Folfiri Plus Bevacizumab (BV). Annals of Oncology, 2012, 23, iv105-iv106.	0.6	0
265	P-0263 Prospective Study of Egfr Intron 1 CA Tandem Repeats as Predictive Factor of Benefit from Cetuximab and Irinotecan. Annals of Oncology, 2012, 23, iv106.	0.6	0
266	Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2012, 138, 1187-1196.	1.2	27
267	Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis, 2012, 15, 275-286.	3.7	61
268	Clinical impact of antiâ€epidermal growth factor receptor monoclonal antibodies in firstâ€line treatment of metastatic colorectal cancer. Cancer, 2012, 118, 1523-1532.	2.0	34
269	PML as a potential predictive factor of oxaliplatin/fluoropyrimidineâ€based first line chemotherapy efficacy in colorectal cancer patients. Journal of Cellular Physiology, 2012, 227, 927-933.	2.0	5
270	Prospective study of EGFR intron 1 CA tandem repeats to predict factor benefit from cetuximab and irinotecan.. Journal of Clinical Oncology, 2012, 30, 3540-3540.	0.8	6

#	Article	IF	Citations
271	Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.. Journal of Clinical Oncology, 2012, 30, LBA385-LBA385.	0.8	34
272	Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer. Expert Opinion on Biological Therapy, 2011, 11, 519-531.	1.4	3
273	Anti-HER agents in gastric cancer: from bench to bedside. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 369-383.	8.2	73
274	Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer, 2011, 11, 247.	1.1	69
275	Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. British Journal of Cancer, 2011, 104, 1786-1790.	2.9	65
276	Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. British Journal of Cancer, 2011, 104, 1262-1269.	2.9	85
277	Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status. Critical Reviews in Oncology/Hematology, 2011, 78, 243-251.	2.0	31
278	Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients With Biliary Tract Cancer (BTC). Current Cancer Drug Targets, 2011, 11, 123-129.	0.8	42
279	Liver metastases from colorectal cancer: how to best complement medical treatment with surgical approaches. Future Oncology, 2011, 7, 1299-1323.	1.1	14
280	Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis. Journal of the National Cancer Institute, 2011, 103, 21-30.	3.0	160
281	Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. Annals of Oncology, 2011, 22, 1141-1146.	0.6	54
282	Correlation of basal EGFR expression with pancreatic cancer grading but not with clinical outcome after gemcitabine-based treatment. Annals of Oncology, 2011, 22, 482-484.	0.6	8
283	Faithful Markers of Circulating Cancer Stem Cells: Is CD133 Sufficient for Validation in Clinics?. Journal of Clinical Oncology, 2011, 29, 3487-3488.	0.8	14
284	Should Oncologists Be Aware in Their Clinical Practice of KRAS Molecular Analysis?. Journal of Clinical Oncology, 2011, 29, e206-e207.	0.8	17
285	Impact ofABCG2polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. Pharmacogenomics, 2011, 12, 159-170.	0.6	63
286	Targeting Vascular Endothelial Growth Factor Pathway in First-Line Treatment of Metastatic Colorectal Cancer: State-of-the-Art and Future Perspectives in Clinical and Molecular Selection of Patients. Current Cancer Drug Targets, 2010, 10, 37-45.	0.8	12
287	Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2010, 66, 559-566.	1.1	5
288	Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?. EPMA Journal, 2010, 1, 495-502.	3.3	22

#	Article	IF	Citations
289	Insulinâ€like growth factor 1 expression correlates with clinical outcome in Kâ€RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. International Journal of Cancer, 2010, 127, 1941-1947.	2.3	67
290	METRONOMIC CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH ADVANCED, CASTRATIONâ€RESISTANT PROSTATE CANCER. Journal of the American Geriatrics Society, 2010, 58, 986-988.	1.3	27
291	Reply: KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?. British Journal of Cancer, 2010, 102, 1076-1077.	2.9	1
292	Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy. Pharmacogenomics, 2010, 11, 1247-1256.	0.6	6
293	High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice. Annals of Oncology, 2010, 21, 1565.	0.6	38
294	Capecitabine after gastrectomy for advanced gastric cancer: have we got the patient right?. Annals of Oncology, 2010, 21, 181.	0.6	5
295	Palliative treatment of unresectable metastatic colorectal cancer. Expert Opinion on Pharmacotherapy, 2010, 11, 63-77.	0.9	18
296	Impact of Cytidine Deaminase Polymorphisms on Toxicity After Gemcitabine: The Question Is Still Ongoing. Journal of Clinical Oncology, 2010, 28, e221-e222.	0.8	21
297	Predictors of Benefit in Colorectal Cancer Treated With Cetuximab: Are We Getting â€œLost in TranslationALâ€?. Journal of Clinical Oncology, 2010, 28, e173-e174.	0.8	4
298	MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity. Cancer Research, 2010, 70, 4528-4538.	0.4	409
299	How useful is adjuvant irinotecan in stage IV CRC?. Nature Reviews Clinical Oncology, 2010, 7, 190-191.	12.5	3
300	Second-line Treatment for Nonâ€“Small-Cell Lung Cancer: One Size Does Not Fit All. Clinical Lung Cancer, 2010, 11, 320-327.	1.1	11
301	Association of Polymorphisms inAKT1andEGFRwith Clinical Outcome and Toxicity in Nonâ€“Small Cell Lung Cancer Patients Treated with Gefitinib. Molecular Cancer Therapeutics, 2010, 9, 581-593.	1.9	67
302	Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncology, The, 2010, 11, 845-852.	5.1	234
303	Genetic modulation of the Let-7 microRNA binding to KRAS 3â€²-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximabâ€“irinotecan. Pharmacogenomics Journal, 2010, 10, 458-464.	0.9	109
304	Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. Journal of Experimental and Clinical Cancer Research, 2010, 29, 58.	3.5	46
305	Metronomic Chemotherapy for Metastatic Prostate Cancer. Drugs and Aging, 2010, 27, 689-696.	1.3	21
306	Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. Annals of Oncology, 2010, 21, 2382-2389.	0.6	94

#	Article	IF	Citations
307	Review: Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2009, 1, 167-181.	1.4	7
308	Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer. Pharmacogenomics Journal, 2009, 9, 78-84.	0.9	23
309	Do we need biopsies of metastases for colorectal cancer patients?. British Journal of Cancer, 2009, 101, 374-375.	2.9	2
310	Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy. British Journal of Cancer, 2009, 100, 881-887.	2.9	164
311	A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. British Journal of Cancer, 2009, 100, 1720-1724.	2.9	30
312	Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. Pharmacogenomics, 2009, 10, 1225-1229.	0.6	7
313	Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients. Expert Opinion on Biological Therapy, 2009, 9, 945-949.	1.4	15
314	Is erlotinib really active after failure of gefitinib in advanced non-small-cell lung cancer patients?. Annals of Oncology, 2009, 20, 790-791.	0.6	6
315	Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer. Clinical Cancer Research, 2009, 15, 4954-4962.	3.2	85
316	Long-Term Outcome of Initially Unresectable Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Followed by Radical Surgery of Metastases. Annals of Surgery, 2009, 249, 420-425.	2.1	213
317	Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. BMC Cancer, 2009, 9, 303.	1.1	66
318	Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. European Journal of Pharmacology, 2009, 619, 8-14.	1.7	35
319	VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population. International Journal of Colorectal Disease, 2009, 24, 165-170.	1.0	47
320	Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen. Clinical and Translational Oncology, 2009, 11, 842-848.	1.2	5
321	A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2009, 63, 965-969.	1.1	15
322	Pharmacokinetics, a main actor in a manyâ€sided approach to severe 5â€FU toxicity prediction. British Journal of Clinical Pharmacology, 2009, 67, 132-134.	1.1	9
323	Refractory neuroendocrine tumorâ€"response to liposomal doxorubicin and capecitabine. Nature Reviews Clinical Oncology, 2009, 6, 670-674.	12.5	5
324	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. British Journal of Cancer, 2009, 101, 715-721.	2.9	509

#	Article	IF	Citations
325	Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). British Journal of Cancer, 2009, 101, 1261-1268.	2.9	130
326	Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer. Lung Cancer, 2009, 66, 327-332.	0.9	12
327	Cisplatin plus Gemcitabine as Adjuvant Chemotherapy for Radically Resected Nonâ€“Small-Cell Lung Cancer: A Pilot Study. Clinical Lung Cancer, 2009, 10, 53-57.	1.1	14
328	PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2009, 27, 2622-2629.	0.8	402
329	Long-Term Outcome of Unresectable Metastatic Colorectal Cancer: Does â€œAdjuvantâ€•Chemotherapy Play a Role After Resection?. Annals of Surgery, 2009, 250, 655.	2.1	0
330	First-Line Systemic Chemotherapy with Folfoxiri Followed by Radical Surgical Resection of Metastases for the Treatment of Unresectable Metastatic Colorectal Cancer Patients. , 2009, , 285-293.		0
331	Baseline elevated leukocyte count in peripheral blood is associated with poor survival in patients with advanced non-small cell lung cancer: a prognostic model. Journal of Cancer Research and Clinical Oncology, 2008, 134, 1143-1149.	1.2	49
332	Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. British Journal of Cancer, 2008, 98, 1619-1629.	2.9	85
333	Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy. British Journal of Cancer, 2008, 99, 716-721.	2.9	29
334	Triplet Combination of Fluoropyrimidines, Oxaliplatin, and Irinotecan in the First-Line Treatment of Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2008, 7, 7-14.	1.0	15
335	Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics Journal, 2008, 8, 278-288.	0.9	97
336	Molecular predictive factors of response to anti-EGFR antibodies in colorectal cancer patients. European Journal of Cancer, Supplement, 2008, 6, 86-90.	2.2	2
337	Pharmacogenetic Profiling for Cetuximab Plus Irinotecan Therapy in Patients With Refractory Advanced Colorectal Cancer. Journal of Clinical Oncology, 2008, 26, 1427-1434.	0.8	124
338	Liver Transplantation for Metastatic Sinonasal Undifferentiated Carcinoma: A Case Report. Transplantation Proceedings, 2008, 40, 3821-3822.	0.3	4
339	Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncology, The, 2008, 9, 39-44.	5.1	130
340	Optimal approach to potentially resectable liver metastases from colorectal cancer. Expert Review of Anticancer Therapy, 2008, 8, 1533-1539.	1.1	4
341	First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study. British Journal of Cancer, 2008, 98, 558-563.	2.9	7
342	A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. British Journal of Cancer, 2008, 98, 1312-1319.	2.9	63

#	Article	IF	Citations
343	5-Fluorouracil Pharmacokinetics Predicts Disease-free Survival in Patients Administered Adjuvant Chemotherapy for Colorectal Cancer. Clinical Cancer Research, 2008, 14, 2749-2755.	3.2	52
344	High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice. Oncologist, 2008, 13, 1270-1275.	1.9	218
345	Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatinâ€"Treated Advanced Nonâ€"Small Cell Lung Cancer Patients. Clinical Cancer Research, 2008, 14, 1797-1803.	3.2	193
346	EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach. Pharmacogenomics, 2008, 9, 55-69.	0.6	12
347	Erlotinib after Failure of Gefitinib in Patients with Advanced Non-small Cell Lung Cancer Previously Responding to Gefitinib. Journal of Thoracic Oncology, 2008, 3, 912-914.	0.5	39
348	First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first?. Current Opinion in Oncology, 2008, 20, 459-465.	1.1	11
349	Cancer Pharmacogenomics: Germline DNA, Tumor DNA, or Both?. Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics, 2007, 5, 87-101.	0.3	3
350	Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest. Journal of Clinical Oncology, 2007, 25, 1670-1676.	0.8	1,083
351	Nuclear Factor-kB Tumor Expression Predicts Response and Survival in Irinotecan-Refractory Metastatic Colorectal Cancer Treated With Cetuximab-Irinotecan Therapy. Journal of Clinical Oncology, 2007, 25, 3930-3935.	0.8	121
352	Vascular Endothelial Growth Factor Levels in Immunodepleted Plasma of Cancer Patients As a Possible Pharmacodynamic Marker for Bevacizumab Activity. Journal of Clinical Oncology, 2007, 25, 1816-1818.	0.8	56
353	Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy. Journal of Clinical Oncology, 2007, 25, 1247-1254.	0.8	250
354	A Pilot Study of a Day One and Eight Every Three Weeks Administration of Docetaxel in Metastatic Cancer Patients. Tumori, 2007, 93, 145-149.	0.6	0
355	Phase II study of sequential chemotherapy with docetaxelâ€"estramustine followed by mitoxantroneâ€"prednisone in patients with advanced hormone-refractory prostate cancer. British Journal of Cancer, 2007, 97, 1613-1617.	2.9	5
356	Chemotherapy intensification. Current Colorectal Cancer Reports, 2007, 3, 116-122.	1.0	0
357	Treatment with 5-Fluorouracil/Folinic Acid, Oxaliplatin, and Irinotecan Enables Surgical Resection of Metastases in Patients With Initially Unresectable Metastatic Colorectal Cancer. Annals of Surgical Oncology, 2006, 13, 58-65.	0.7	156
358	Capecitabine and Mitomycin c May be an Effective Treatment Option for Third-line Chemotherapy in Advanced Colorectal Cancer. Tumori, 2006, 92, 384-388.	0.6	17
359	A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. Clinical Pharmacology and Therapeutics, 2006, 80, 384-395.	2.3	63
360	Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation. Cancer Chemotherapy and Pharmacology, 2006, 58, 585-593.	1.1	13

#	Article	IF	Citations
361	Second-Line Chemotherapy with a Modified Schedule of Docetaxel in Elderly Patients with Advanced-Stage Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 2006, 7, 401-405.	1.1	19
362	First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. Annals of Oncology, 2006, 17, 1249-1254.	0.6	22
363	Reply to the Letter to the Editor on â€˜Cost-opportunity analysis in clinical oncology: from the â€œwild far-westâ€•to a correct integration of the disciplines, avoiding the â€œwar of the worldsâ€â€™, by D. Tassinari et al. (Ann Oncol 2006; 17: 876). Annals of Oncology, 2006, 17, 877-878.	0.6	0
364	Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase Iâ€“II study. British Journal of Cancer, 2006, 94, 1263-1266.	2.9	6
365	Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer. Tumori, 2006, 92, 384-8.	0.6	7
366	Improved Analysis of 5-Fluorouracil and 5,6-Dihydro-5-Fluorouracil by HPLC With Diode Array Detection for Determination of Cellular Dihydropyrimidine Dehydrogenase Activity and Pharmacokinetic Profiling. Therapeutic Drug Monitoring, 2005, 27, 362-368.	1.0	24
367	Adjuvant sequential methotrexate â†’ 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer. British Journal of Cancer, 2005, 92, 24-29.	2.9	16
368	Cyclophosphamide-methotrexate â€˜metronomicâ€™ chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Annals of Oncology, 2005, 16, 1243-1252.	0.6	91
369	A Phase I and Pharmacokinetic Study of Irinotecan Given as a 7-Day Continuous Infusion in Metastatic Colorectal Cancer Patients Pretreated with 5-Fluorouracil or Raltitrexed. Clinical Cancer Research, 2004, 10, 1657-1663.	3.2	23
370	First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Annals of Oncology, 2004, 15, 1766-1772.	0.6	99
371	A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. British Journal of Cancer, 2004, 91, 1996-2004.	2.9	158
372	5-Fluorouracil Administered as a 48-Hour Semiintermittent Infusion in Combination With Leucovorin, Cisplatin and Epirubicin. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 101-105.	0.6	2
373	Hypersensitivity reactions related to oxaliplatin (OHP). British Journal of Cancer, 2003, 89, 477-481.	2.9	113
374	Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC). Annals of Oncology, 2003, 14, 1365-1372.	0.6	25
375	Biweekly Chemotherapy With Oxaliplatin, Irinotecan, Infusional Fluorouracil, and Leucovorin: A Pilot Study in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2002, 20, 4006-4014.	0.8	148
376	Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report. European Journal of Clinical Pharmacology, 2002, 58, 593-595.	0.8	17
377	Cholinergic toxic syndrome by the anticancer drug irinotecan: Acetylcholinesterase does not play a major role. Clinical Pharmacology and Therapeutics, 2002, 71, 263-271.	2.3	6
378	Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer. Clinical Pharmacology and Therapeutics, 2002, 72, 627-637.	2.3	23

#	Article	IF	Citations
379	Sequence Effect of Irinotecan and Fluorouracil Treatment on Pharmacokinetics and Toxicity in Chemotherapy-Naive Metastatic Colorectal Cancer Patients. Journal of Clinical Oncology, 2001, 19, 3456-3462.	0.8	51
380	5-Fluorouracil Administered as a 48-Hour Chronomodulated Infusion in Combination with Leucovorin and Cisplatin: A Randomized Phase II Study in Metastatic Colorectal Cancer. Oncology, 2001, 61, 28-35.	0.9	9
381	Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Annals of Oncology, 2001, 12, 1301-1306.	0.6	94
382	Oral Doxifluridine in Advanced Hepatocellular Carcinoma: A Phase II Study. Oncology, 2000, 59, 204-209.	0.9	7
383	Infusions of Fluorouracil and Leucovorin: Effects of the Timing and Semi-Intermittency of Drug Delivery. Oncology, 1999, 57, 195-201.	0.9	22
384	Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II study. Cancer Chemotherapy and Pharmacology, 1999, 44, 159-163.	1.1	14
385	Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. , 1999, 86, 470-476.		30
386	Pharmacokinetic Optimisation of the Treatment of Cancer with High Dose Zidovudine. Clinical Pharmacokinetics, 1998, 34, 173-180.	1.6	10
387	Biochemical Modulation by 5-Fluorouracil and 1-Folinic Acid of Tumor Uptake of Intra-Arterial 5-[123I]Iodo-2'-Deoxyuridine in Patients with Liver Metastases from Colorectal Cancer. Acta OncolÃ³gica, 1996, 35, 941-945.	0.8	14
388	Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients.. Journal of Clinical Oncology, 1996, 14, 729-736.	0.8	19
389	Phase II Study of Oral Doxifluridine in Elderly Patients with Advanced Non-Small-Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1996, 19, 592-594.	0.6	9
390	Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II Study. Cancer, 1995, 75, 440-443.	2.0	16
391	Double 5-Fluorouracil Modulation with Folinic Acid and Recombinant Alpha-2B-Interferon. American Journal of Clinical Oncology: Cancer Clinical Trials, 1994, 17, 210-214.	0.6	3
392	Alpha-2B-interferon plus floxuridine in metastatic renal cell carcinoma a phase I-II study. Cancer, 1993, 72, 564-568.	2.0	11
393	Recombinant Î±-2a Interferon Plus Vinblastine in the Treatment of Metastatic Renal Cell Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 1989, 12, 43-45.	0.6	20
394	Moving-Strip Abdomino-Pelvic Radiotherapy After cis-Platinum-Based Chemotherapy and Second-Look Operation A Feasibility Study in Advanced Ovarian Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1988, 11, 16-20.	0.6	8
395	Regional Pharmacokinetic Selectivity of Intraperitoneal Cisplatin in Ovarian Cancer. Oncology, 1988, 45, 69-73.	0.9	3